Modern methods of introduction of patients with poor ovarian response to controlled ovarian stimulation: A literature review
DOI:
https://doi.org/10.37800/RM.4.2024.283Keywords:
poor ovarian response, assisted reproduction technology (ART), controlled ovarian stimulation, POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number), adjuvant therapyAbstract
Relevance: Poor ovarian response to controlled ovarian stimulation is a serious problem that occurs during in vitro fertilization and embryo transfer procedures. Many women undergoing controlled ovarian stimulation may suffer from a poor ovarian response (POR), and its frequency tends to increase in young patients. Among women who receive controlled ovarian stimulation, the frequency of POR reached 9-24%.
The study aimed to determine the effectiveness and safety of regimens, including adjuvant therapy with controlled ovarian stimulation with POR.
Materials and Methods: A literature search was performed on all types of clinical trials in Russian and English, according to the following keywords and phrases related to the topic methods of introduction of patients with a poor ovarian response: "poor ovarian response," "adjuvant therapy," "Poseidon group," "controlled ovarian stimulation", "assisted reproduction technology." The review used scientific databases such as PubMed, Scopus, Web of Science, and Google Scholar. The criteria for selecting literature included relevance (publications devoted to this topic no older than 10 years) of research to the review topic and the availability of full texts of articles.
Results: Comparing ovarian response to adjuvant therapy with an alternative stimulation protocol showed that in some cases, adjuvant therapy showed better results.
Conclusion: This review shows that the proposed strategies and pharmaceutical methods for treating POR significantly increased the number of eggs extracted during the ovarian cycle, the number of viable embryos, and live birth rates. These results indicate that additional adjuvant treatment (DHEA, Coenzyme Q10) during controlled ovarian stimulation is the optimal method of managing patients with POR.
References
Polyzos N, Drakopoulos P, Parra J, Pellicer A, Santos-Ribeiro S, Tournaye H, Bosch E, Garcia-Velasco J. Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women. Fertil Steril. 2018;110:661-670.
https://doi.org/10.1016/j.fertnstert.2018.04.039
Panagiotis D, Erlisa B, Liese B, Alberto V, Antonis M, Sandro CE, Herman T, Christophe B. Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept. Ther Adv Reprod Health. 2020;14.
https://doi.org/10.1177/2633494120941480
Boza A, Oguz SY, Misirlioglu S. Utilization of the Bologna criteria: a promise unfulfilled? A review of published and unpublished/ongoing trials. Fertil Steril. 2018;109:104-109.
https://doi.org/10.1016/j.fertnstert.2017.09.024
Younis JS, Ben-Ami M, Ben-Shlomo I. The Bologna criteria for poor ovarian response: a contemporary critical appraisal. J Ovarian Res. 2015;8:76.
https://doi.org/10.1186/s13048-015-0204-9
Sandro CE, Matheus R, Giuliano MB, Alessandro C, Humaidan P, Alviggi C. Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria–The Why. Front Endocrinol (Lausanne). 2018;9:461.
https://doi.org/10.3389/fendo.2018.00461
Madani T, Hemat M, Arabipoor A, Khodabakhshi SH, Zolfaghari Z. Double mild stimulation and egg collection in the same cycle to manage poor ovarian responders. J. Gynecol. Obstet. Hum. Reprod. 2019;48(5):329-333. https://doi.org/10.1016/j.jogoh.2018.12.004
Vaiarelli A, Cimadomo D, Argento C, Ubaldi N, Trabucco E, Drakopoulos P. Double stimulation in the same ovarian cycle (DuoStim) is an intriguing strategy to improve oocyte yield and the number of competent embryos in a short timeframe. Minerva Ginecol. 2019;71(5):372-376.
https://doi.org/10.23736/S0026-4784.19.04390-9
Massin N. New stimulation regimens: endogenous and exogenous progesterone used to block the LH surge during ovarian stimulation for IVF. Hum. Reprod. Upd. 2017;23(2): 211-220.
https://doi.org/10.1093/humupd/dmw047
Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X. Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing In vitro Fertilization Treatment: A Randomized Controlled Trial. Front. Endocrinol. (Lausanne). 2019;10:796. https://doi.org/10.3389/fendo.2019.00796
Zhenni M, Yuanhong S, Zhengao S, Yang Y. Ovulation induction with high progesterone levels may be more suitable for elderly patients with low ovarian response. J. Gynecol. Obstet. Hum. Reprod. 2021; 50(2):101661.
https://doi.org/10.1016/j.jogoh.2019.101661
Chen Q, Wang Y, Sun L, Zhang S, Chai W, Hong Q. Controlled ovulation of the dominant follicle using progestin in minimal stimulation in poor responders. Reprod. Biol. Endocrinol. 2017;15(1):71.
https://doi.org/10.1186/s12958-017-0291-0
Dong J, Wang Y, Chai WR, Hong QQ, Wang NL, Sun LH. The pregnancy outcome of progestin-primed ovarian stimulation using four versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilization: a randomized controlled trial. BJOG. 2017;124(7):1048-1055.
https://doi.org/10.1111/1471-052814622
Dai X, Wang Y, Yang H, Gao T, Yu C, Cao F, Xia X, Wu J, Zhou X, Chen L. AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles. Sci Rep. 2020;12:10(1):19750.
https://doi.org/10.1038/s41598-020-76543-y.
Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC. ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod. Biomed. Online. 2019;38(2):195-205.
https://doi.org/10.1016/j.rbmo
Tilborg TC, Broekmans FJ, Dólleman M, Eijkemans MJ, Mol BW, Laven JS. Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstet. Gynecol. Scand. 2016;95(12):1333-1344.
https://doi.org/10.1111/aogs.13032
Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, Kunicki M, Marca AL, Lainas G, Clef NL, Massin N, Mastenbroek S, Polyzos N, Kamal Sunkara S, Timeva T, Töyli M, Urbancsek J, Vermeulen N, Broekmans F. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum. Reprod Open. 2020;2:hoaa009. https://doi.org/10.1093/hropen/hoaa009
Qin Y. Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: A meta-analysis. J. Gynecol. Obstet. Hum. Reprod. 2021;50(8):102139.
https://doi.org/10.1016/j.jogoh.2021.102139
Bastu E, Buyru F, Ozsurmeli M, Demiral I, Dogan M, Yeh J. A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without the addition of letrozole during ovulation stimulation in patients with poor ovarian response. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016;203:30-34. https://doi.org/10.1016/j.ejogrb.2016.05.027
Kamath MS, Maheshwari A, Bhattacharya S, Lor KY, Gibreel A. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilization. Cochrane Database Syst. Rev. 2017;11(11):CD008528.
https://doi.org/10.1002/14651858
Maged AM, Nada AM, Abohamila F, Hashem AT, Mostafa WA, Elzayat AR. Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase: A Randomized Controlled Trial. Reprod. Sci. 2015;22(12):1627-1631.
https://doi.org/10.1177/1933719115590666
Merviel P, Cabry-Goubet R, Lourdel E, Devaux A, Belhadri-Mansouri N, Copin H, Benkhalifa M. Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy. Reprod. Health. 2015;12:52.
https://doi.org/10.1186/s12978-015-0039-2
Schimberni M, Ciardo F, Schimberni M, Giallonardo A, De Pratti V, Sbracia M. Short gonadotropin-releasing hormone agonist versus flexible antagonist versus clomiphene citrate regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. Eur. Rev. Med. Pharmacol. Sci. 2016;20(20):4354-4361. https://www.europeanreview.org/article/11610
Siristatidis C, Salamalekis G, Dafopoulos K, Basios G, Vogiatzi P, Papantoniou N. Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI. In Vivo. 2017;31(2):231-237.
https://doi.org/10.21873/invivo.11050
Lambalk CB, Banga FR, Huirne JA, Toftager M, Pinborg A, Homburg R, F van der Veen, M van Wely. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum. Reprod. Upd. 2017;23(5):560-579. https://doi.org/10.1093/humupd/dmx017
Toftager M, Bogstad J, Bryndorf T, Lossl K, Rocker J, Holland T. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum. Reprod. 2016;31(6):1253-1264. https://doi.org/10.1093/humrep/dew051
Li W, Zhang W, Zhao H, Chu Y, Liu X. Efficacy of the depot gonadotropin-releasing hormone agonist protocol on in vitro fertilization outcomes in young, poor ovarian responders from POSEIDON group 3. Int. J. Gynaecol. Obstet. 2022;157(3):733-740. https://doi.org/10.1002/ijgo.13933
Haas J, Zilberberg E, Nahum R, Mor Sason A, Hourvitz A, Gat I. Does double trigger (GnRH-agonist + hCG) improve outcomes in poor responders undergoing the IVF-ET cycle? A pilot study. Gynecol. Endocrinol. 2019;35(7):628-630. https://doi.org/10.1080/09513590.2019.1576621
Gizzo S, Andrisani A, Noventa M, Manfè S, Oliva A, Gangemi M. Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the optimal daily dose and timing. Mol. Med. Rep. 2015;12(3):4219-4229.
https://doi.org/10.3892/mmr.2015.3904
Younis JS, Laufer N. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone therapy in gonadotropin-releasing hormone analog cycles: what is the evidence. Curr. Med. Res. Opin. 2018;34(5):881-886. https://doi.org/10.1080/03007995.2017.1417827
Humaidan P, Chin W, Rogoff D, D'Hooghe T, Longobardi S, Hubbard J. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum. Reprod. 2017;32(3):544-555. https://doi.org/10.1093/humrep/dew360
Noushin MA, Sahu A, Singh S, Singh S, Jayaprakasan K, Basheer R. Dehydroepiandrosterone (DHEA) role in enhancement and maintenance of implantation (DREAM): randomized double-blind placebo-controlled trial-study protocol. BMJ Open. 2021;11(10):e054251.
https://doi.org/10.1136/bmjopen-2021-054251
Neves AR, Montoya-Botero P, Polyzos NP. The Role of Androgen Supplementation in Women With Diminished Ovarian Reserve: Time to Randomize, Not Meta-Analyze. Front. Endocrinol. (Lausanne). 2021;12:653857. https://doi.org/10.3389/fendo.2021.653857
Elprince M, Kishk EA, Metawie OM, Albiely MM. Ovarian stimulation after dehydroepiandrosterone supplementation in poor ovarian reserve: a randomized clinical trial. Arch. Gynecol. Obstet. 2020;302(2):529–534.
https://doi.org/10.1007/s00404-020-05603-5
Bosdou JK, Venetis CA, Dafopoulos K, Zepiridis L, Chatzimeletiou K, Anifandis G. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial. Hum. Reprod. 2016;31(5):977–985. https://doi.org/10.1093/humrep/dew028
Noventa M, Vitagliano A, Andrisani A, Blaganje M, Viganò P, Papaelo E. Testosterone therapy for women with poor ovarian response undergoing IVF: a meta-analysis of randomized controlled trials. J. Assist. Reprod. Genet. 2019;36(4):673-683. https://doi.org/10.1007/s10815-018-1383-2
Lattes K, Brassesco M, Gomez M, Checa MA. Low-dose growth hormone supplementation increases clinical pregnancy rate in poor responders undergoing in vitro fertilization. Gynecol. Endocrinol. 2015;31(7):565-568. https://doi.org/10.3109/09513590.2015.1025378
Bassiouny YA, Dakhly DMR, Bayoumi YA, Hashish NM. Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial. Fertil. Steril. 2016;105(3):697-702.
https://doi.org/10.1016/j.fertnstert.2015.11.026
Dakhly DM, Bayoumi YA, Gad Allah SH. Which is the best IVF/ICSI protocol for use in poor responders receiving growth hormone as an adjuvant treatment? A prospective randomized trial. Gynecol. Endocrinol. 2016;32(2):116-119. https://doi.org/10.3109/09513590.2015.1092136
Li XL, Wang L, Lv F, Huang XM, Wang LP, Pan Y. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(12):e6443.
https://doi.org/10.1097/MD.0000000000006443
Norman RJ, Hart RJ. Human growth hormone use in poor ovarian response – caution and opБООtunities. Ther. Adv. Reprod. Heal. 2021;15:15. https://doi.org/10.1177/2633494121999420
Caprio F, D'Eufemia MD, Trotta C, Campitiello MR, Ianniello R, Mele D. Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial. J. Ovarian Res. 2015;8(37).
https://doi.org/10.1186/s13048-015-0167-x
Nazari L, Salehpour S, Hosseini S, Saharkhiz N, Azizi E, Hashemi T. Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial. J. Gynecol. Obstet. Hum. Reprod. 2020;49(5):P. 101698. https://doi.org/10.1016/j.jogoh.2020.101698
Mohammadi S, Eini F, Bazarganipour F, Taghavi SA, Kutenaee MA. The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial. Reprod. Biol. Endocrinol. 2021;19(1):61.
https://doi.org/10.1186/s12958-021-00741-0
Xu Y, Nisenblat V, Lu C. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial. Reprod. Biol. Endocrinol. 2018;16:29. https://doi.org/10.1186/s12958-018-0343-0
Gat I, Blanco MS, Balakier H, Librach CL, Claessens A, Ryan EA. The use of coenzyme Q10 and DHEA during IUI and IVF cycles in patients with decreased ovarian reserve. Gynecol. Endocrinol. 2016;32(7):534–537. https://doi.org/10.3109/09513590.2015.1137095
Sfakianoudis K, Simopoulou M, Grigoriadis S, Pantou A, Tsioulou P, Maziotis E, Rapani A, Giannelou P, Nitsos N, Kokkali G, Koutsilieris M, Pantos K. Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. J. Clin. Med. 2020;9(6):1809
https://doi.org/10.3390/jcm9061809
Herraiz S, Romeu M, Buigues A, Martínez S, Díaz-García C, Gomez-Seguí I, Martínez J, Pellicer N, Pellicer A. Autologous stem cell ovarian transplantation to increase reproductive potential in patients who are poor responders. Fertil. Steril. 2018;2:496-505. https://doi.org/10.1016/j.fertnstert.2018.04.025
Li Z, Zhang M, Tian Y, Li Q, Huang X. Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects. Front. Cell Dev. Biol. 2021;9:1-13. https://doi.org/10.3389/fcell.2021.718192
Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood. 2007;109(8). https://doi.org/10.1182/blood-2006-03-013433
Kawamuraa K, Ishizuka B, Aaron JWH. Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve. RBMO. 2020;40:245-253.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The rights to a manuscript accepted for publication are transferred to the Journal Publisher. When reprinting all or part of the material, the author must refer to the primary publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
